Curi Bio and Battelle Forge Strategic Alliance to Advance New Approach Methods in Neuromuscular Pharmacology
Curi Bio, a recognized leader in the development of human-relevant three-dimensional (3D) tissue platforms, has entered into a strategic partnership with Battelle, the world’s largest independent nonprofit research and development organization, in a move aimed at accelerating the commercialization and adoption of next-generation Neuromuscular Junction (NMJ) assay technologies. This collaboration represents a significant step forward in the evolution of pharmacological testing, combining cutting-edge biological modeling with large-scale infrastructure and regulatory expertise to reshape how neuromuscular therapies are evaluated and developed.
At the heart of this partnership is a shared vision to modernize drug discovery and development processes by transitioning away from traditional animal-based models toward more predictive, human-relevant systems. By integrating Curi Bio’s advanced microphysiological systems with Battelle’s extensive Good Laboratory Practice (GLP)-ready capabilities, the two organizations aim to deliver a scalable and practical solution that aligns with evolving scientific, ethical, and regulatory expectations.
A central pillar of the collaboration is its strong alignment with the principles of the 3Rs—Replacement, Reduction, and Refinement—which guide efforts to minimize the use of animals in scientific research. Historically, neuromuscular pharmacology has relied heavily on animal-based bioassays to evaluate the potency and safety of therapeutics, particularly in areas such as botulinum neurotoxin (BoNT) testing. While these methods have been foundational, they often present limitations in terms of translational relevance, reproducibility, and ethical considerations.
Through this partnership, Curi Bio and Battelle aim to address these challenges by offering functional, 3D human tissue models that closely replicate the complexity of human neuromuscular physiology. These models provide researchers with the ability to study drug effects in a biologically relevant context, enabling more accurate predictions of human responses. By doing so, they not only reduce dependence on animal testing but also enhance the overall quality and consistency of pharmacological data.
Curi Bio’s proprietary Mantarray™ platform plays a pivotal role in this initiative. The Mantarray ecosystem is designed to deliver real-time functional readouts of contractility in engineered human tissues, including cardiac, skeletal muscle, and neuromuscular junction systems. This capability allows scientists to directly measure the physiological impact of compounds on tissue function, providing insights that go beyond traditional endpoint assays.
One of the most promising applications of this technology lies in BoNT potency testing. Botulinum neurotoxins are widely used in both therapeutic and cosmetic applications, and their development requires precise and reliable potency assessments. By offering a ready-to-use, human cell-based NMJ assay, Curi Bio enables pharmaceutical and biotechnology companies to generate product-specific data with greater confidence and efficiency. This not only accelerates development timelines but also supports regulatory compliance in an increasingly stringent environment.
Battelle’s role in the partnership is equally critical, serving as the scale and integration partner responsible for translating innovative technologies into real-world applications. With decades of experience in managing complex research programs and operating advanced laboratory facilities, Battelle brings the infrastructure needed to implement NMJ assay technologies across diverse development pipelines. This includes support for drug substances as well as medical countermeasures (MCMs), an area of growing importance in global health preparedness.
In addition to its technical capabilities, Battelle offers deep regulatory expertise, which is essential for the successful adoption of new approach methods (NAMs). As regulatory agencies around the world continue to update their guidelines to encourage the use of non-animal models, organizations must navigate a complex landscape of validation, standardization, and compliance requirements. Battelle’s experience in this domain ensures that the technologies developed through this partnership are not only scientifically robust but also aligned with regulatory expectations.
The timing of this collaboration is particularly significant, as the broader regulatory and funding environment is increasingly supportive of alternatives to animal testing. Recent guidance from the U.S. Food and Drug Administration (FDA) on the use of Non-Animal Models (NAMs), along with substantial investments from institutions such as the National Institutes of Health (NIH), underscores a growing commitment to advancing human-relevant research methodologies. These developments create a favorable backdrop for the adoption of platforms like those offered by Curi Bio and Battelle.
Elliot Fisher, Chief Business Officer and Co-Founder of Curi Bio, emphasized the strategic importance of the partnership in light of these trends. He highlighted that the collaboration represents a high-priority initiative for the company as it seeks to establish a new gold standard for potency testing. By leveraging Battelle’s capabilities, Curi Bio aims to scale its technology to meet both commercial and governmental needs, positioning itself at the forefront of the transition toward animal-free drug development.
From Battelle’s perspective, the partnership exemplifies the power of combining innovation with implementation. Bob Moyer, a Research Leader at Battelle, noted that the collaboration brings together complementary strengths—Curi Bio’s cutting-edge technology and Battelle’s expertise in scaling and integration. This synergy enables the translation of scientific breakthroughs into practical solutions that can be deployed across the pharmaceutical and biotechnology industries.
Beyond its immediate applications, the partnership also has broader implications for the future of biomedical research. As the industry continues to embrace more sophisticated and human-relevant models, technologies like NMJ assays are expected to play an increasingly important role in areas such as disease modeling, drug screening, and personalized medicine. By providing a platform that accurately reflects human biology, these systems have the potential to improve the success rates of drug development programs and reduce the time and cost associated with bringing new therapies to market.
Moreover, the adoption of NAMs aligns with growing societal expectations סביב ethical research practices. Stakeholders—including regulators, patients, and advocacy groups—are calling for more humane and sustainable approaches to scientific discovery. By prioritizing the 3Rs and investing in innovative alternatives, organizations like Curi Bio and Battelle are helping to address these concerns while advancing the frontiers of science.
The partnership also highlights the importance of collaboration in driving innovation. In an increasingly complex and interdisciplinary landscape, no single organization can address all aspects of drug development on its own. By joining forces, Curi Bio and Battelle are able to leverage their respective expertise to create a solution that is greater than the sum of its parts. This collaborative model is likely to become more prevalent as the industry continues to evolve.
Looking ahead, the success of this initiative will depend on several key factors, including the continued validation and standardization of NMJ assay technologies, the willingness of industry stakeholders to adopt new methodologies, and the ongoing support of regulatory agencies. However, with strong scientific foundations, robust infrastructure, and a clear alignment with emerging trends, the partnership is well positioned to achieve its أهداف.
In conclusion, the strategic alliance between Curi Bio and Battelle represents a transformative خطوة in the field of neuromuscular pharmacology. By combining innovative 3D tissue models with scalable, GLP-ready infrastructure, the collaboration offers a compelling alternative to traditional testing methods. As the industry moves toward more human-relevant and ethically responsible approaches, this partnership stands out as a leading example of how innovation and collaboration can drive meaningful change in drug development.
About Curi Bio: Curi Bio provides a suite of human-relevant 3D tissue models and instrumentation to accelerate drug discovery and development. By integrating human iPSCs, tissue engineering, and automated data analysis, Curi Bio helps researchers build more predictive models of human disease. For more information, visit www.curibio.com or contact Marketing Director Jacqueline De Rose at jacqueline@curibio.com.
About Battelle: Every day, the people of Battelle apply science and technology to solving what matters most. At major technology centers and national laboratories around the world, Battelle conducts research and development, designs and manufactures products, and delivers critical services for government and commercial customers.
Source Link: https://www.businesswire.com/
